Cel­cu­ity has pro­vid­ed fur­ther de­tails on why the com­mer­cial roll­out of its re­cent­ly ap­proved can­cer drug is slow­er than in­vestors ini­tial­ly an­tic­i­pat­ed.

The drug­mak­er said...

Sev­en large drug­mak­ers and lob­by­ing groups PhRMA and BIO have called up­on the Ger­man gov­ern­ment to re­vise some of its new drug pric­ing poli­cies as...

Plus, SK pharmte­co’s Ire­land ex­pan­sions. 

🇨🇳 WuXi Bio to di­vest Shang­hai sub­sidiary: The com­pa­ny is sell­ingits 51.1% eq­ui­ty stake in chro­matog­ra­phy resin sup­pli­er Bestchrom...

Tavneos’ with­draw­al from the Eu­ro­pean mar­ket is cre­at­ing chal­lenges for CSL Vi­for.

CSL Lim­it­ed, Vi­for’s Aus­tralian par­ent com­pa­ny, said Vi­for’s rev­enue is ex­pect­edto fall...

Mod­er­na has been say­ing for years that it would di­ver­si­fy its port­fo­lio be­yond in­fec­tious dis­eases. In­vestors were wait­ing for late-stage proof.

On Wednes­day, they got...